Editas Medicine, Inc.

NasdaqGS:EDIT Stok Raporu

Piyasa değeri: US$270.2m

Editas Medicine Yönetim

Yönetim kriter kontrolleri 2/4

Editas Medicine CEO'su Gilmore O’Neill, Jun2022 tarihinde atandı, in görev süresi 3.92 yıldır. in toplam yıllık tazminatı $ 2.35M olup, şirket hissesi ve opsiyonları dahil olmak üzere 29.2% maaş ve 70.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.17% ine doğrudan sahiptir ve bu hisseler $ 453.13K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.7 yıl ve 7.3 yıldır.

Anahtar bilgiler

Gilmore O’Neill

İcra Kurulu Başkanı

US$2.4m

Toplam tazminat

CEO maaş yüzdesi29.17%
CEO görev süresi3.9yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi1.7yrs
Yönetim Kurulu ortalama görev süresi7.3yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • May 14

Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)

The analysts covering Editas Medicine, Inc. ( NASDAQ:EDIT ) delivered a dose of negativity to shareholders today, by...
Analiz Makalesi • May 08

Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates

The first-quarter results for Editas Medicine, Inc. ( NASDAQ:EDIT ) were released last week, making it a good time to...
Analiz Makalesi • Nov 13

Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

A week ago, Editas Medicine, Inc. ( NASDAQ:EDIT ) came out with a strong set of quarterly numbers that could...
Analiz Makalesi • Nov 05

Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop

Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have retraced a considerable 29% in the last month, reversing a fair...
Analiz Makalesi • Nov 02

Here's Why We're A Bit Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 14

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Summary Gene editing seems like a great idea: instead of masking the symptoms of disease, we actually change the genes to bring permanent change that actually removes the disease. The platform used nowadays to do this is known as CRISPR. I previously covered two companies, CRISPR Therapeutics and Intellia Therapeutics, that license and use this intellectual property. Editas Medicine is also a CRISPR licensee. But it failed twice, with treatments aimed at eye disease and sickle cell disease/beta thalassemia. And its stock suffered badly. With two strikes against it, EDIT is back in the batter’s box. And unlike peers that attack small-population problems, EDIT is swinging at the mass market, high LDL ("bad") cholesterol. It’s way too early to gauge potential success. But given a big target market, pioneering in-the-body editing, and a beaten-down stock, EDIT's reward-risk balance tilts toward ‘Buy.’. Read the full article on Seeking Alpha
Analiz Makalesi • Sep 09

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have been powering on, with a gain of 26...
Analiz Makalesi • Jul 22

There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump

Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have continued their recent momentum with a 42% gain in the last month...
Analiz Makalesi • Jun 17

Editas Medicine (NASDAQ:EDIT) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • May 21

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders are no doubt pleased to see that the share price has bounced 28% in...
Analiz Makalesi • Mar 30

Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has softened a substantial 35% over the previous 30 days, handing...
Analiz Makalesi • Mar 13

We're A Little Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jan 17

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

Summary Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despite market pessimism. Intellia's advanced clinical-stage programs and a clear path to market support a speculative “Buy” rating for long-term NTLA investors with a high-risk tolerance. Editas' in vivo CRISPR pipeline is still in the early stages, leading to a temporary “Hold” rating for EDIT stock until more clarity on targeted indications and clinical results is provided. Both companies face high risks, including potential off-target effects and market volatility, requiring cautious investment and risk mitigation strategies. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 20

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has fared very poorly over the last month, falling by a...
Analiz Makalesi • Nov 06

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making...
Analiz Makalesi • Sep 26

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Sep 25

Editas Medicine: A Risk/Reward Worth Considering

Summary Editas Medicine has made significant progress in advancing reni-cel, their in-vivo editing pipeline, and business development, despite a 65% drop in stock price. Reni-cel shows promising clinical results for sickle cell disease and beta-thalassemia, with potential BLA submission by year-end, enhancing its risk-reward profile. Editas' in-vivo pipeline and strategic partnerships bolster its position, but competition and regulatory challenges remain significant risks. EDIT's current valuation and potential market growth present an attractive investment opportunity, with a speculative yet promising outlook for long-term gains. Read the full article on Seeking Alpha
Analiz Makalesi • Aug 23

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has fared very poorly over the last month, falling by a...
Analiz Makalesi • Aug 10

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

As you might know, Editas Medicine, Inc. ( NASDAQ:EDIT ) last week released its latest second-quarter, and things did...
Analiz Makalesi • May 12

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

As you might know, Editas Medicine, Inc. ( NASDAQ:EDIT ) last week released its latest quarterly, and things did not...
Analiz Makalesi • Apr 23

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

To the annoyance of some shareholders, Editas Medicine, Inc. ( NASDAQ:EDIT ) shares are down a considerable 25% in the...
Analiz Makalesi • Mar 09

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Those holding Editas Medicine, Inc. ( NASDAQ:EDIT ) shares would be relieved that the share price has rebounded 28% in...
Seeking Alpha • Feb 28

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Summary Results from the Editas Medicine, Inc. phase 1/2 studies using reni-cel for the treatment of patients with Sickle-Cell Disease and Transfusion dependent thalassemia are expected in mid-2024 and end of 2024. The global Sickle-Cell Disease treatment market size is expected to be worth $7.79 billion by 2032. The global thalassemia treatment market is expected to reach $1.5 billion by end of 2031. Editas Medicine can overcome competition with owning several CRISPR Cas9 patents and the differentiation of using Cas12a nuclease, which might have greater selectivity and efficiency over Cas9a CRISPR candidates. Read the full article on Seeking Alpha
Analiz Makalesi • Dec 15

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making...
Analiz Makalesi • May 10

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Celebrations may be in order for Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders, with the analysts delivering a...

CEO Tazminat Analizi

Gilmore O’Neill'un ücretlendirmesi Editas Medicine'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$109m

Dec 31 2025US$2mUS$687k

-US$160m

Sep 30 2025n/an/a

-US$200m

Jun 30 2025n/an/a

-US$237m

Mar 31 2025n/an/a

-US$251m

Dec 31 2024US$5mUS$667k

-US$237m

Sep 30 2024n/an/a

-US$211m

Jun 30 2024n/an/a

-US$193m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$2mUS$641k

-US$153m

Sep 30 2023n/an/a

-US$195m

Jun 30 2023n/an/a

-US$206m

Mar 31 2023n/an/a

-US$219m

Dec 31 2022US$9mUS$356k

-US$220m

Tazminat ve Piyasa: Gilmore 'nin toplam tazminatı ($USD 2.35M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.66M ).

Tazminat ve Kazançlar: Gilmore 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Gilmore O’Neill (61 yo)

3.9yrs
Görev süresi
US$2,353,655
Tazminat

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Gilmore O’Neill
President3.9yrsUS$2.35m0.17%
$ 453.1k
Amy Parison
Senior VP & CFO1.2yrsUS$821.66k0.0073%
$ 19.8k
Linda Burkly
Executive VP & Chief Scientific Officer2.8yrsUS$1.18m0.029%
$ 79.5k
Feng Zhang
Co-Founder & Scientific Advisory Board Member13.3yrsVeri yokVeri yok
George Church
Co-Founder & Scientific Advisory Board Member13.3yrsVeri yokVeri yok
Gregory Whitehead
Executive VP and Chief Technical & Quality Officer2.1yrsVeri yokVeri yok
Damien Grierson
Senior VP1.3yrsVeri yokVeri yok
Tom Love
Vice President of Peopleless than a yearVeri yokVeri yok
Frank Panaccio
Senior VP & Chief Business Officer1.3yrsVeri yokVeri yok
Brieana Buckley
Senior Vice President of Development and Program Leadership1.3yrsVeri yokVeri yok
1.7yrs
Ortalama Görev Süresi
64.5yo
Ortalama Yaş

Deneyimli Yönetim: EDIT 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Gilmore O’Neill
Presidentno dataUS$2.35m0.17%
$ 453.1k
Feng Zhang
Co-Founder & Scientific Advisory Board Memberno dataVeri yokVeri yok
George Church
Co-Founder & Scientific Advisory Board Memberno dataVeri yokVeri yok
Andrew Hirsch
Independent Director9yrsUS$118.71k0.0020%
$ 5.5k
Jessica Hopfield
Independent Chairman8.3yrsUS$146.21k0.069%
$ 186.9k
Elliott Levy
Independent Director3.1yrsUS$101.21k0%
$ 0
David Scadden
Independent Director7.3yrsUS$99.96k0%
$ 0
Bernadette Connaughton
Independent Director4.6yrsUS$112.46k0%
$ 0
7.3yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: EDIT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/25 06:09
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Editas Medicine, Inc. 25 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jack AllenBaird
Joel BeattyBaird
Alec StranahanBofA Global Research